Company news
Protagonist Therapeutics, Inc. news in 2023
Protagonist Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
December 12, 2023
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
December 11, 2023
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
November 26, 2023
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
November 8, 2023
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
November 1, 2023
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 1, 2023
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
October 31, 2023
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
October 29, 2023
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
October 8, 2023
Protagonist Therapeutics to Present at Upcoming Investor Conferences
September 4, 2023
Protagonist Receives $34 Million from Warrant Exercises
August 8, 2023
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 2, 2023
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
July 3, 2023
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects o...
June 8, 2023
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
June 5, 2023
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
May 31, 2023
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113
May 11, 2023
Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference
May 10, 2023
Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association
May 10, 2023
Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 3, 2023
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
April 3, 2023
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
April 3, 2023
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 14, 2023
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
March 14, 2023
Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis
March 6, 2023
Decks in 2023
- Investor Presentation (July 2023)
Investor deck · 58 slides · Jul 5, 2023